Recommended Pages at galenica.com
Galenica.com - CellCept reaches positive results in Phase III trial in Lupus Nephritis
galenica.com — “Vifor Pharma, the pharma business sector of the Galenica Group, and Roche (SIX: RO, ROG; OTCQX: RHHBY), today announced that the maintenance phase of the Aspreva Lupus Man-agement Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche's CellCept (mycophenolate mofetil) versus azathioprine (AZA) in de-laying treatment failure in patients with Lupus Nephritis (LN). ALMS is one of the largest stud-ies ever conducted in LN.” View full resource at galenica.com
Most Recently Shared on September 22, 2010 at 4:12 pm By:
Lupus Doctor Doctor, Internist, Rheumatologist, and Physician
ALMSTrialCellCept vs AZA rx in patients who responded to CYT or AZA inductionMMF superior to AZA in delaying rx failure http://bit.ly/9f1pD0
